<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>Johnson &amp; Johnson buys eye disease biotech for up to $3.3bn — Live Feed</title><link>https://www.live-feeds.com/feed/johnson-johnson-buys-eye-disease-biotech-for-up-to-3-3bn</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/johnson-johnson-buys-eye-disease-biotech-for-up-to-3-3bn/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>Johnson &amp; Johnson acquires Ollin Biosciences for up to $3.3bn</title><link>https://www.live-feeds.com/feed/johnson-johnson-buys-eye-disease-biotech-for-up-to-3-3bn</link><guid isPermaLink="false">https://www.live-feeds.com/feed/johnson-johnson-buys-eye-disease-biotech-for-up-to-3-3bn#u209908</guid><pubDate>Fri, 20 Nov 2026 06:27:00 +0000</pubDate><description>Johnson &amp;amp; Johnson agreed to buy Austin-based Ollin Biosciences for $2.2 billion upfront plus milestone payments that could raise the total value to $3.3 billion. The deal adds a Phase III bispecific antibody candidate targeting wet age-related macular degeneration and diabetic macular edema, positioning J&amp;amp;J to compete with Roche&amp;#039;s Vabysmo in the ophthalmology market.Why it mattersThe acquisition bolsters J&amp;amp;J&amp;#039;s ophthalmology pipeline with a late-stage asset that could challenge the current standard of care. Ollin&amp;#039;s bispecific antibody is designed to inhibit two pathwa</description></item>
</channel></rss>